ABSTRACT
BACKGROUND AND OBJECTIVES: High recurrence rates of Stages II and IIIA melanoma make close follow-up essential, especially with new adjuvant therapies for metastatic disease. However, there are currently no consensus guidelines for routine imaging for Stages IIB, IIC, and IIIA melanoma. The study's aim is to determine the utility of 18 F-fluorodeoxyglucose (18 F-FDG) positron emission tomography/computed tomography (PET/CT) for detecting asymptomatic recurrence of melanoma after primary surgical resection. METHODS: This retrospective cohort study included 158 patients with the American Joint Committee on Cancer 8th edition Stages IIB, IIC, or IIIA cutaneous melanoma who underwent an 18 F-FDG PET/CT from 2010 to 2020. We retrospectively analyzed clinical data after a median follow-up time of 39 months. RESULTS: We calculated a positive predictive value (PPV) of 32% (95% confidence interval: 11%-53%) for 154 routine PET/CTs, including six true positives and 13 false positives (FPs). PPV was 33% for Stage IIB, 50% for Stage IIC, and 14% for Stage IIIA. FPs were mostly benign or inflammatory foci (75%), and some other malignancies were found (21%). CONCLUSIONS: This cohort of patients imaged for high-risk melanoma demonstrated a high FP rate and low PPV. These findings suggest that routine surveillance with 18 F-FDG PET/CT may not be indicated for monitoring recurrence in this population.
Subject(s)
Fluorodeoxyglucose F18 , Melanoma/diagnostic imaging , Neoplasm Recurrence, Local/diagnostic imaging , Positron Emission Tomography Computed Tomography , Radiopharmaceuticals , Skin Neoplasms/diagnostic imaging , Aged , Aged, 80 and over , Asymptomatic Diseases , Female , Humans , Male , Melanoma/pathology , Melanoma/therapy , Middle Aged , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Predictive Value of Tests , Retrospective Studies , Skin Neoplasms/pathology , Skin Neoplasms/therapyABSTRACT
Prognosis among patients with stage III melanoma can vary widely depending on the risk of disease relapse. Therefore, it is vital to optimize patient care through accurate diagnosis and staging as well as thoughtful treatment planning. A multidisciplinary team (MDT) approach, which involves active collaboration among physician specialists across a patient's disease journey, has been increasingly adopted as the standard of care for treatment of a variety of cancers, including melanoma. This review provides an overview of MDT care principles for patients with BRAF-mutant-positive, stage III cutaneous melanoma and summarizes current literature, clinical experiences, and institutional best practices. Therapeutic goals from dermatologic, surgical, and medical oncologist perspectives regarding MDT care throughout a patient's disease course are discussed. Additionally, the role of each specialty's involvement in testing for predictive biomarkers at relevant time points to facilitate informed treatment decisions is discussed. Last, instances of successful MDT treatment of other cancers and key lessons to optimize MDT patient care in cutaneous melanoma are provided. Several aspects of MDT patient care are considered vital, such as the importance of staging via pathological examination and imaging, biomarker testing, and interdisciplinary physician and patient engagement throughout the course of treatment. Use of MDTs has the potential to improve patient care in cutaneous melanoma by improving the speed and accuracy of diagnosis, implementing a personalized treatment plan early on, and being proactive in adverse event management. Physician perspectives described in this review may lead to better outcomes, quality of life, and overall patient satisfaction. IMPLICATIONS FOR PRACTICE: As more cancer therapies emerge, it is critical to optimize patient care and treatment planning. The multidisciplinary team (MDT) approach, which involves active collaboration among specialists, has led to encouraging survival results in multiple cancer types. As MDT care becomes more widely adopted in the treatment of melanoma, accurate diagnosis and staging are important, as clinical outcomes for stage III disease vary widely by substage. Because ~50% of melanomas harbor BRAF mutations, testing is important for an informed treatment decision. Interdisciplinary physician-patient engagement throughout the course of treatment can improve comorbidity and adverse event management to optimize patients' treatment journeys.
Subject(s)
Melanoma , Oncologists , Skin Neoplasms , Humans , Melanoma/diagnosis , Melanoma/genetics , Melanoma/therapy , Patient Care Team , Proto-Oncogene Proteins B-raf/genetics , Quality of Life , Skin Neoplasms/diagnosis , Skin Neoplasms/genetics , Skin Neoplasms/therapyABSTRACT
Checkpoint inhibitors have been revolutionary in the treatment of metastatic melanoma, non-small-cell lung cancer, and renal cell carcinoma. By restricting negative feedback of T-cells, checkpoint inhibitors allow the immune system to identify and destroy malignant cells. This enhanced immune response is efficacious in the treatment of the aforementioned malignancies; however, it may lead to immune-related adverse events. Bullous pemphigoid (BP) is a well-documented cutaneous adverse reaction of checkpoint inhibitors, with a majority of cases reporting an eosinophil-predominant or mixed inflammatory infiltrate. We report two cases of neutrophil-predominant BP presenting in patients on checkpoint inhibitors.
Subject(s)
Immune Checkpoint Inhibitors/adverse effects , Melanoma/drug therapy , Neutrophils/pathology , Pemphigoid, Bullous/chemically induced , Pemphigoid, Bullous/pathology , Skin/pathology , Aged , Antimalarials/administration & dosage , Antimalarials/therapeutic use , Dapsone/administration & dosage , Dapsone/therapeutic use , Drug Eruptions/pathology , Drug Therapy, Combination , Glucocorticoids/administration & dosage , Glucocorticoids/therapeutic use , Humans , Immune Checkpoint Inhibitors/therapeutic use , Lung Neoplasms/secondary , Male , Melanoma/pathology , Pemphigoid, Bullous/drug therapy , Pemphigoid, Bullous/metabolism , Prednisone/administration & dosage , Prednisone/therapeutic use , Treatment OutcomeABSTRACT
BACKGROUND: Melanoma incidence has increased; the primary modifiable risk factor is ultraviolet radiation (UVR) from the sun or artificial UVR (arUVR) from tanning beds. OBJECTIVE: To determine whether patients who developed melanoma after arUVR exposure from tanning beds have unique characteristics. METHODS: A retrospective study of 434 melanoma patients was performed. Patients who consented at the initial appointment completed a questionnaire regarding phenotypic traits, medical history, and UVR exposure. RESULTS: Compared with patients aged ≥40 years, younger patients, especially women, had greater lifetime exposure to arUVR. At any age, patients with multiple primary melanomas had a higher probability of exposure to arUVR. For all patients with additional primary melanomas, those exposed to arUVR acquired their second primary melanoma significantly earlier; 67% of patients exposed to arUVR through tanning beds had their second primary diagnosed at the time of or within 1 year of their original diagnosis compared with 28% of nontanners (P = .011). Median time to diagnosis of second primary melanoma in patients exposed to arUVR versus those not exposed was 225 days versus 3.5 years, respectively (P = .027). LIMITATIONS: The study was conducted in 1 geographic area with a relatively small sample size. CONCLUSION: Our findings provide evidence for heightened surveillance in melanoma patients exposed to arUVR.
Subject(s)
Cosmetic Techniques/adverse effects , Melanoma/etiology , Neoplasms, Radiation-Induced/etiology , Neoplasms, Second Primary/etiology , Skin Neoplasms/etiology , Ultraviolet Rays/adverse effects , Adolescent , Adult , Aged , Aged, 80 and over , Cosmetic Techniques/instrumentation , Disease Susceptibility , Ethnicity , Female , Hair Color , Humans , Male , Melanoma/epidemiology , Middle Aged , Neoplasms, Radiation-Induced/epidemiology , Neoplasms, Second Primary/epidemiology , Radiation Exposure , Registries , Retrospective Studies , Risk , Skin Neoplasms/epidemiology , Skin Pigmentation , Sunburn/epidemiology , Sunscreening Agents , Time Factors , Washington/epidemiology , Young AdultSubject(s)
Melanoma , Quality of Life , Skin Neoplasms , Adult , Aged , Female , Humans , Male , Melanoma/drug therapy , Melanoma/pathology , Middle Aged , Neoplasm Staging , Skin Neoplasms/drug therapy , Skin Neoplasms/pathologyABSTRACT
Despite advances in treatment and surveillance, melanoma continues to claim approximately 9,000 lives in the US annually (SEER 2013). The National Comprehensive Cancer Network currently recommends ipilumumab, vemurafenib, dabrafenib, and high-dose IL-2 as first line agents for Stage IV melanoma. Little data exists to guide management of cutaneous and subcutaneous metastases despite the fact that they are relatively common. Existing options include intralesional Bacillus Calmette-Guérin, isolated limb perfusion/infusion, interferon-α, topical imiquimod, cryotherapy, radiation therapy, interferon therapy, and intratumoral interleukin-2 injections. Newly emerging treatments include the anti-programmed cell death 1 receptor agents (nivolumab and pembrolizumab), anti-programmed death-ligand 1 agents, and oncolytic vaccines (talimogene laherparepevec). Available treatments for select sites include adoptive T cell therapies and dendritic cell vaccines. In addition to reviewing the above agents and their mechanisms of action, this review will also focus on combination therapy as these strategies have shown promising results in clinical trials for metastatic melanoma treatment.
Subject(s)
Immunotherapy/methods , Melanoma/secondary , Melanoma/therapy , Skin Neoplasms/pathology , Skin Neoplasms/therapy , Biological Products/therapeutic use , Cancer Vaccines/therapeutic use , Clinical Trials, Phase I as Topic , Combined Modality Therapy , Female , Humans , Injections, Intralesional , Interferons/therapeutic use , Male , Melanoma/pathology , Mohs Surgery/methods , Molecular Targeted Therapy/methods , Neoplasm Invasiveness/pathology , Neoplasm Metastasis , Neoplasm Staging , Prognosis , Randomized Controlled Trials as Topic , Risk Assessment , SEER Program , Treatment OutcomeABSTRACT
We developed handheld photoacoustic microscopy (PAM) to detect melanoma and determine tumor depth in nude mice in vivo. Compared to our previous PAM system for melanoma imaging, a new light delivery mechanism is introduced to improve light penetration. We show that melanomas with 4.1 and 3.7 mm thicknesses can be successfully detected in phantom and in in vivo experiments, respectively. With its deep melanoma imaging ability and handheld design, this system can be tested for clinical melanoma diagnosis, prognosis, and surgical planning for patients at the bedside.
Subject(s)
Fiber Optic Technology/instrumentation , Melanoma/diagnostic imaging , Melanoma/pathology , Microscopy, Acoustic/instrumentation , Photoacoustic Techniques/instrumentation , Skin Neoplasms/diagnostic imaging , Skin Neoplasms/pathology , Animals , Cell Line, Tumor , Equipment Design , Equipment Failure Analysis , Mice , Mice, Nude , Miniaturization , Neoplasm InvasivenessABSTRACT
BACKGROUND: Activating mutations in BRAF have been observed in up to 60% of melanomas, indicating a pivotal role for kinase deregulation in tumor progression. Vemurafenib is a specific inhibitor of BRAF for treatment of melanomas with activating BRAF V600E mutations and has been a major advancement in melanoma treatment. Treatment with vemurafenib, and to a lesser extent, sorafenib, a relatively non-specific inhibitor of BRAF, has been associated with cutaneous squamous cell carcinoma (SCC). METHODS: Clinical and microscopic characteristics of cutaneous neoplasms were evaluated following vemurafenib administration. RESULTS: Twenty-four of 47 (51%) patients receiving vemurafenib at our institution developed 146 total cutaneous neoplasms, with 75% developing multiple lesions. The median number of lesions in affected patients was three. Body distribution included head/neck (29%), chest/back (21%), upper (23%) and lower extremities (27%). Lesions were biopsied and pathologically showed multiple types of epidermal tumors including, but not limited to, verrucous keratoses with/without partial thickness dysplasia, actinic keratoses and well-differentiated and invasive SCCs with/without keratoacanthomatous features. CONCLUSIONS: We describe the histopathologic findings of skin lesions potentially associated with vemurafenib. Additional investigation is necessary to further elucidate cutaneous neoplasms associated with vemurafenib; however, frequent dermatologic evaluation is warranted in all patients receiving BRAF inhibitors.
Subject(s)
Indoles/adverse effects , Keratoacanthoma/chemically induced , Keratoacanthoma/pathology , Melanoma/drug therapy , Neoplasms, Second Primary/pathology , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Skin Neoplasms/chemically induced , Skin Neoplasms/pathology , Sulfonamides/adverse effects , Adult , Aged , Aged, 80 and over , Humans , Indoles/administration & dosage , Keratoacanthoma/enzymology , Keratoacanthoma/genetics , Male , Melanoma/enzymology , Melanoma/genetics , Middle Aged , Mutation , Neoplasms, Second Primary/enzymology , Neoplasms, Second Primary/genetics , Proto-Oncogene Proteins B-raf/genetics , Skin Neoplasms/enzymology , Skin Neoplasms/genetics , Sulfonamides/administration & dosage , VemurafenibABSTRACT
Introduction: NRAS mutations are common in melanoma and confer a worse prognosis. Although most patients with metastatic melanoma receive immune checkpoint inhibitors (ICIs), the impact of NRAS mutational status on their efficacy remains under debate. Methods: We performed a comprehensive literature search across several large databases. Inclusion criteria were trials, cohorts, and large case series that analyzed the primary outcome of objective response rate by NRAS mutational status in patients with melanoma treated with any line of ICI. At least two reviewers independently screened studies using Covidence software, extracted data, and assessed risk of bias. Standard meta-analysis was performed in R with sensitivity analysis and tests for bias. Results: Data on 1770 patients from ten articles were pooled for meta-analysis, and the objective response rate to ICIs was calculated to compare NRAS-mutant and NRAS-wildtype melanoma. The objective response rate was 1.28 (95% confidence interval: 1.01-1.64). Sensitivity analysis identified the study by Dupuis et al. with influential impact on the pooled effect size and heterogeneity, favoring NRAS-mutant melanoma. Discussion: In this meta-analysis evaluating the impact of NRAS mutational status on objective response to ICIs in metastatic melanoma, NRAS-mutant cutaneous melanoma demonstrated an increased likelihood of partial or complete tumor response, relative to NRAS-wildtype cutaneous melanoma. Genomic screening for NRAS mutations in patients with metastatic melanoma may improve predictive ability when initiating ICIs.
ABSTRACT
Rap1 is expressed in human umbilical vein endothelial cells (HUVECs). Rap1-GTPase activating protein (Rap1GAP), with its specific target, Rap1, has been shown to be important in the regulation of many physiological and certain pathological processes. In this study, we investigated the effect of Rap1GAP expression on endothelial cell function, or, more specifically, proliferation and migration of endothelial cells. HUVECs were transfected with pcDNA3.1 (empty vector), pcDNA3.1 containing Flag-tagged-Rap1GAP or Myc-tagged-Rap1N17. The proliferation, migration and tube formation were examined and compared among the 3 groups. Expression of Rap1, Rap1GAP, extracellular signal-regulated kinase (ERK), phospho-ERK, Akt, phosphor-Akt was detected by Western blotting. The results showed that the proliferation, migration and tube formation were significantly reduced in Rap1GAP- and Rap1N17-transfected HUVECs as compared with empty vector-transfected control. These changes were coincident with increased expression of Rap1GAP and decreased expression of activated Rap1, phospho-ERK and -Akt. After treatment of Rap1GAP-transfected HUVECs with a stimulator of Rap1 guanine-nucleotide-exchange factor (Rap1GEF) 8CPT-2'OMe-cAMP, it was found that Rap1 activity was decreased as compared with empty vector-transfected control. Pretreatment of HUVECs with an ERK inhibitor PD98059 or a PI3K inhibitor LY294002 prior to stimulation not only blocked 8CPT-2'OMe-cAMP-induced phosphorylation of ERK and Akt, but also significantly reduced cell proliferation and migration. Finally, we examined the effect of vascular endothelial growth factor (VEGF) on HUVECs overexpressing Rap1GAP. VEGF-stimulated Rap1 activity, phosphorylation of ERK and Akt, cyclin D1 expression and cell proliferation were repressed in HUVECs overexpressing Rap1GAP as compared to empty vector-transfected control. Taken together, our findings demonstrate that Rap1GAP/Rap1 and their downstream effectors regulate proliferation and migration of HUVECs via ERK and Akt pathways.
Subject(s)
Cell Movement , Cell Proliferation , Extracellular Signal-Regulated MAP Kinases/metabolism , GTPase-Activating Proteins/biosynthesis , Human Umbilical Vein Endothelial Cells/cytology , Adaptor Proteins, Signal Transducing/metabolism , Apoptosis Regulatory Proteins/metabolism , Cells, Cultured , GTPase-Activating Proteins/genetics , Human Umbilical Vein Endothelial Cells/metabolism , Humans , Signal Transduction , TransfectionABSTRACT
SIGNIFICANCE: Detection and characterization of circulating tumor cells (CTCs), a key determinant of metastasis, are critical for determining risk of disease progression, understanding metastatic pathways, and facilitating early clinical intervention. AIM: We aim to demonstrate label-free imaging of suspected melanoma CTCs. APPROACH: We use a linear-array-based photoacoustic tomography system (LA-PAT) to detect melanoma CTCs, quantify their contrast-to-noise ratios (CNRs), and measure their flow velocities in most of the superficial veins in humans. RESULTS: With LA-PAT, we successfully imaged suspected melanoma CTCs in patients in vivo, with a CNR >9. CTCs were detected in 3 of 16 patients with stage III or IV melanoma. Among the three CTC-positive patients, two had disease progression; among the 13 CTC-negative patients, 4 showed disease progression. CONCLUSIONS: We suggest that LA-PAT can detect suspected melanoma CTCs in patients in vivo and has potential clinical applications for disease monitoring in melanoma.
Subject(s)
Melanoma/diagnostic imaging , Neoplastic Cells, Circulating/pathology , Photoacoustic Techniques , Skin Neoplasms/diagnostic imaging , Tomography , Animals , Cell Count , Female , Flow Cytometry , Humans , Male , Melanoma/pathology , Melanoma, Experimental/diagnostic imaging , Melanoma, Experimental/pathology , Mice , Middle Aged , Neoplasm Staging , Phantoms, Imaging , Sensitivity and Specificity , Skin Neoplasms/pathology , Tumor Cells, CulturedABSTRACT
The risks of developing malignant melanoma (MM) include ultraviolet irradiation and genetic factors. To examine the contribution of rare and common variation within known MM genes in sporadic US MM patients, coding regions of known MM susceptibility genes [cyclin-dependent kinase inhibitor 2A (CDKN2A), cyclin-dependent kinase 4, melanocortin 1 receptor (MC1R) and tyrosinase (TYR)] were resequenced in 109-135 MM cases. The significance of variants was examined by comparing their frequencies in 390 cancer-free controls. Potential deleterious mutations in CDKN2A were found in two patients and two others had variants of unknown significance. Cases were more likely than controls to harbour the MC1R'R' variants known or predicted to alter its function (P = 0.002), particularly the R160W variant (P = 0.0035). The associated TYR R402Q variant (rs1126809*A) was found in 29% of cases, similar to what has been described previously. One MM patient with a family history of MM, who had developed other skin cancers, was homozygous for a novel TYR variant (P406L) of unknown significance. Hence, rare variants in TYR may be important risk factors for skin cancer.
Subject(s)
Genetic Predisposition to Disease , Melanoma/epidemiology , Melanoma/genetics , Skin Neoplasms/epidemiology , Skin Neoplasms/genetics , Cyclin-Dependent Kinase Inhibitor p16/genetics , Exons , Genetic Variation , Homozygote , Humans , Introns , Mutation , Receptor, Melanocortin, Type 1/genetics , Risk Factors , Sequence Analysis, DNA , Ultraviolet Rays , United StatesABSTRACT
The major modifiable risk factor in melanomagenesis is UV exposure and mutagenesis of melanocytes. Other UV-induced events that contribute to early tumorigenesis are poorly understood. Herein we show that the repeated exposure of human primary melanocytes to UVB results in a sustained senescence response, increases in expression of signal transducer and activator of transcription 1, MX1, OAS2, and IRF7 proteins of up to 75-fold, and resistance to subsequent UVB-induced apoptosis. In the setting of UVB-induced DNA damage, we detected time-dependent increases in the release of damage-associated molecular patterns such as high-mobility group box 1 (HMGB1). After intermittent UVB exposure, melanocytes treated with the JAK inhibitor ruxolitinib reduced expression of HMGB1 and MX1 as well as activation of JAK1 (pJAK1) and signal transducer and activator of transcription 1 (pSTAT1). In addition, melanocytes expressing small hairpin RNA selective for the HMGB1 receptor, receptor for advanced glycosylation end product (RAGE), exhibited decreased expression of both HMGB1 and MX1 after UVB exposure. The response of small hairpin RAGE-infected cells to human recombinant HMGB1 was blunted with decreased MX1 expression and JAK activation. Finally, depletion of receptor for advanced glycosylation end product decreased UVB-induced resistance to apoptosis (P < 0.05). These findings highlight a cell autonomous response to UV damage, contribute to their resistance to apoptosis and cell death, and may have implications for early stages of melanoma development.
Subject(s)
Apoptosis , Gene Expression Regulation, Neoplastic , HMGB1 Protein/genetics , Melanocytes/metabolism , Melanoma/genetics , Receptor for Advanced Glycation End Products/genetics , Ultraviolet Rays/adverse effects , DNA Damage/radiation effects , DNA, Neoplasm/genetics , HMGB1 Protein/biosynthesis , Humans , Inflammation/genetics , Inflammation/metabolism , Inflammation/pathology , Melanocytes/pathology , Melanocytes/radiation effects , Melanoma/metabolism , Melanoma/pathology , Polymerase Chain Reaction , Receptor for Advanced Glycation End Products/biosynthesis , Signal TransductionABSTRACT
BACKGROUND: Topical calcipotriol plus 5-fluorouracil (5-FU) combination is an effective immunotherapy against actinic keratosis (AK), which is a precursor to squamous cell carcinoma (SCC). However, the long-term effectiveness of calcipotriol plus 5-FU treatment for SCC prevention is unknown. METHODS: We performed a blinded prospective cohort study on participants of a randomized double-blind clinical trial in which a 4-day course of topical calcipotriol plus 5-FU combination was compared to Vaseline plus 5-FU (control) for AK treatment. SCC and basal cell carcinoma (BCC) incidences were assessed at 1, 2, and 3 years after trial. Tissues were analyzed for calcipotriol plus 5-FU-induced T cell immunity in the skin. RESULTS: Calcipotriol plus 5-FU-induced tissue-resident memory T (Trm) cell formation in face and scalp skin associated with significantly higher erythema scores compared with control (P < 0.01). Importantly, more participants in the test cohort remained SCC-free over the more than 1,500-day follow-up period (P = 0.0765), and significantly fewer developed SCC on the treated face and scalp within 3 years (2 of 30 [7%] versus 11 of 40 [28%] in control group, hazard ratio 0.215 [95% CI: 0.048-0.972], P = 0.032). Accordingly, significantly more epidermal Trm cells persisted in the calcipotriol plus 5-FU-treated face and scalp skin compared with control (P = 0.0028). There was no significant difference in BCC incidence between the treatment groups. CONCLUSION: A short course of calcipotriol plus 5-FU treatment on the face and scalp is associated with induction of robust T cell immunity and Trm formation against AKs and significantly lowers the risk of SCC development within 3 years of treatment. FUNDING: This research was supported by internal academic funds and by grants from the Burroughs Wellcome Fund, Sidney Kimmel Foundation, Cancer Research Institute, and NIH.
Subject(s)
Carcinoma, Squamous Cell/therapy , Immunotherapy/methods , Skin Neoplasms/therapy , Adaptive Immunity , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols , Calcitriol/analogs & derivatives , Calcitriol/pharmacology , Calcitriol/therapeutic use , Carcinoma, Basal Cell , Carcinoma, Squamous Cell/pathology , Double-Blind Method , Female , Fluorouracil/pharmacology , Fluorouracil/therapeutic use , Humans , Male , Middle Aged , Prospective Studies , Skin/immunology , Skin/pathology , Skin Neoplasms/immunology , Skin Neoplasms/pathologyABSTRACT
BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) is not uncommon in association with indolent malignancies that were treated with prior radiotherapy and after allogenic bone marrow transplantation. On the other hand, cutaneous T-cell lymphoma (CTCL) is a subtype of non-Hodgkin's lymphoma which is characterized by an indolent course, with relative refractoriness to conventional chemotherapies and radiotherapy, and occasionally referred for allogeneic hematopoietic cell transplantation (allo-HCT). Recently, the use of immune checkpoint inhibitors has gained attention in the treatment of both cutaneous squamous cell carcinoma and hematological malignancies. However, many patients with hematological malignancies eventually undergo allo-HCT, raising the concern of potential adverse events (graft versus host disease) due to manipulation of the immune system with use of checkpoint inhibitors. CASE PRESENTATION: We describe a patient with relapsed refractory CTCL (Sézary Syndrome) who underwent allo-HCT with persistence of disease post-transplant. The patient additionally developed a progressively worsening lesion on the right shoulder which was biopsied and showed poorly differentiated carcinoma (cSCC). Pembrolizumab was started for the treatment of cSCC. After second cycle of treatment, the cSCC lesion responded dramatically to the use of immune checkpoint inhibitor. Also, the patient experienced significant resolution of pruritus and generalized erythema. During 24 months of follow up after initial treatment with checkpoint inhibition immunotherapy, the patient showed durable response of both cSCC and CTCL, as well as restoration of full donor chimerism, without obvious worsening of graft versus host disease (GVHD). CONCLUSION: This is the first case to our knowledge of rapid and durable response of both cSCC and CTCL to immune checkpoint inhibition after allo-HCT. Although this report highlights the potential for significant response to this class of medication, further studies are required to confirm the efficacy and safety of this approach in patients with CTCL after allo-HCT given the potential concern of GVHD.
Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Carcinoma, Squamous Cell/therapy , Molecular Targeted Therapy , Sezary Syndrome/therapy , Antineoplastic Agents, Immunological/administration & dosage , Antineoplastic Agents, Immunological/adverse effects , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/etiology , Combined Modality Therapy , Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/methods , Humans , Male , Middle Aged , Positron Emission Tomography Computed Tomography , Postoperative Care , Sezary Syndrome/diagnosis , Sezary Syndrome/etiology , Skin/pathology , Transplantation, Homologous , Treatment OutcomeABSTRACT
IMPORTANCE: Extramammary Paget disease (EMPD), a rare intraepithelial adenocarcinoma, poses a therapeutic challenge with high postoperative recurrence rates and a limited number of effective local treatment options. OBJECTIVE: To describe the use and efficacy of a topical combination of fluorouracil and calcipotriene as a palliative therapy for refractory EMPD. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series of 3 women with recurrent, refractory EMPD was conducted at Beth Israel Deaconess Medical Center, Boston, Massachusetts and Washington University School of Medicine, St Louis, Missouri. All patients were treated with a 1:1 mixture of fluorouracil, 5%, cream and calcipotriene, 0.005%, cream or ointment. MAIN OUTCOMES AND MEASURES: Clinical and histopathological findings. RESULTS: All 3 women (1 in her 50s, 2 in their 70s) presented with recurrent EMPD (vulvar, perianal, and perioral) after surgery and/or irradiation, and their EMPD was refractory to treatment with imiquimod, 5%, cream. Owing to disease progression and/or intolerable adverse effects from imiquimod, the patients began treatment with a 1:1 mixture of fluorouracil, 5%, cream and calcipotriene, 0.005%, cream. This treatment, which was well tolerated, was followed by clinical improvement in symptoms and appearance of the lesions in all 3 cases and histopathological signs of decreased tumor burden in 2 cases. Patients applied the combination topical therapy to affected areas with differing frequencies, ranging from 1 to 2 days per month to 4 consecutive days every 2 weeks. CONCLUSIONS AND RELEVANCE: Extramammary Paget disease frequently recurs even after aggressive surgical management and can be refractory to many topical and locoregional therapies. Palliative treatment with a combination of fluorouracil and calcipotriene may be a viable option for patients with recurrent, refractory EMPD.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Paget Disease, Extramammary/drug therapy , Palliative Care/methods , Skin Neoplasms/drug therapy , Administration, Topical , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Calcitriol/administration & dosage , Calcitriol/analogs & derivatives , Female , Fluorouracil/administration & dosage , Humans , Imiquimod/administration & dosage , Middle Aged , Paget Disease, Extramammary/pathology , Retrospective Studies , Treatment OutcomeABSTRACT
Matrix metalloproteinases (MMP) have been implicated in virtually all aspects of tumor progression. However, the recent failure of clinical trials employing synthetic MMP inhibitors in cancer chemotherapy has led us to hypothesize that some MMPs may actually serve the host in its defense against tumor progression. Here we show that mice deficient in macrophage elastase (MMP-12) develop significantly more gross Lewis lung carcinoma pulmonary metastases than their wild-type counterparts both in spontaneous and experimental metastasis models. The numbers of micrometastases between the two groups are equivalent; thus, it seems that MMP-12 affects lung tumor growth, and not metastasis formation, per se. MMP-12 is solely macrophage derived in this model, being expressed by tumor-associated macrophages and not by tumor or stromal cells. The presence of MMP-12 is associated with decreased tumor-associated microvessel density in vivo and generates an angiostatic>angiogenic tumor microenvironment that retards lung tumor growth independent of the production of angiostatin. These data define a role for MMP-12 in suppressing the growth of lung metastases and suggest that inhibitors designed to specifically target tumor-promoting MMPs may yet prove effective as cancer therapeutics.
Subject(s)
Carcinoma, Lewis Lung/enzymology , Carcinoma, Lewis Lung/secondary , Macrophages, Alveolar/enzymology , Metalloendopeptidases/deficiency , Angiostatins/biosynthesis , Animals , Carcinoma, Lewis Lung/blood supply , Cell Growth Processes/physiology , Endothelial Cells/enzymology , Endothelial Cells/pathology , Female , Male , Matrix Metalloproteinase 12 , Melanoma, Experimental/enzymology , Melanoma, Experimental/pathology , Metalloendopeptidases/genetics , Metalloendopeptidases/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Neovascularization, Pathologic/enzymology , Neovascularization, Pathologic/pathology , PhenotypeABSTRACT
IMPORTANCE: Head and neck melanoma is one of the leading causes of death in the United States and is currently increasing in prevalence. While there is a tremendous amount of research published on melanoma, the actual evidence for complex clinical decision-making can be difficult to interpret and to stay up-to-date on current clinical standards. OBJECTIVE: To address, in a systematic and evidence-based approach, the most common clinical controversies with regard to the workup and management of head and neck melanoma. EVIDENCE REVIEW: A PubMed and Medline search was performed of the entire English literature with respect to head and neck melanoma. Priority of review was given to those studies with higher-quality levels of evidence. FINDINGS: Main topics reviewed in this article include workup for new melanoma, surgical treatment of the primary site, surgical treatment of the neck, adjuvant radiation therapy, and systemic therapy. Levels of evidence are used for each controversial clinical question to help the clinician understand the reliability of the current evidence when making complex clinical decisions for melanoma management of the head and neck. However, much of the work done in melanoma, particularly large randomized clinical trials, includes many other regions of the body. Therefore, these data must be interpreted in light of the potential differences in clinical behavior and draining lymphatics between trunk, limbs, and head and neck subsites. CONCLUSIONS AND RELEVANCE: The management of head and neck melanoma requires a multidisciplinary approach, particularly for advanced-stage disease. An in-depth knowledge of the current evidence available will help guide the surgeon in the management of this difficult disease.